International: +1-347-960-6455
Mitochondrial-Based Therapeutics Pipeline Analysis 2019

Mitochondrial-Based Therapeutics Pipeline Analysis 2019, Clinical Trials and Results, Patents, Designations, Collaborations, and Other Developments

Report Code: PP10212 Published: September 2019 Pages: 133 Available format: 
Therapeutic Area(s): Oncology | Immunology | Metabolic | Respiratory | Infectious | Ophthalmology | Gastroenterology | Nephrology | Neurology | Urology Report Type: Mechanism of Action Reports
Select License Type
Note: This report can also be updated as of date and delivered within 1-2 working days of purchase confirmation


Mitochondria (singular: mitochondrion) are cytoplasmic organelles found in eukaryotic cells, such as plants, animals, fungi, and protists. The number of mitochondria present in a eukaryotic cell depend on the metabolic requirements of that cell; and ranges from a single large mitochondrion to thousands of the organelles. Mitochondria generate adenosine tri-phosphate (ATP) through oxidative phosphorylation, and also plays a key role in apoptosis., Mitochondrial therapeutic development is focused on diseases, which are caused by mutations in mitochondrial deoxyribonucleic acid (DNA) or in nuclear gene encoding mitochondrial protein.

Mitochondrial disorders are diagnosed by complete physical examination; neurological examination; metabolic examinations, including urine and blood tests; reviewing a patient’s family history; and cerebral spinal fluid test.

Currently, there is no therapy approved for the treatment of disease caused by mitochondrial dysfunction. However, several mitochondrial-based drugs are under clinical trials for treating a range of diseases. Stealth BioTherapeutics Inc.’s drug candidate, Elamipretide, has reached the late stage of clinical development.

Further, technological advancement is a major factor that supports the drug development process. Due to advancements in drug development technologies, many pharmaceutical companies are leveraging improved and advanced technologies for the development of mitochondrial-based therapeutics.

These technologies are helpful in the development of drugs either in the form of combination therapies or single-agent therapies. They allow development of specific targeted therapies with better drug delivery. For instance, CohBar’s technology platform is specifically designed to rapidly identify therapeutically relevant peptides encoded within the mitochondrial genome. This further helps in evaluating their biological activity and developing these peptides into novel mitochondrial-based therapeutics that have the potential to treat diseases with major unmet medical needs.

Pipeline Analysis

As of August 2019, the mitochondrial-based therapeutics pipeline comprises of 27 drugs in different stages of development.


Mitochondrial-Based Therapeutics

Competitive Landscape

Some of the key players involved in the development of mitochondrial-based drugs are Stealth BioTherapeutics Inc., CohBar Inc., and Astellas Pharma Inc.

Report Insights

Some highlights of the Mitochondrial-Based Therapeutics Pipeline Analysis 2019, Clinical Trials and Results, Patents, Designations, Collaborations and Other Developments report are as below:

  • Detailed pipeline analysis of therapeutic candidates that are being developed for the treatment of diseases, and estimates and analyses of emerging therapies and their progress status in different phases of development
  • Comprehensive insights into pipeline products, with special focus on strategic developments of key players, information on drug licensing, designations, financing, and grants, technological advancements, patents, and upcoming conferences
  • Competitive analysis and extensive information on monotherapies, combination therapies, targets and mechanisms of action, and drug origin with relevance to mitochondrial-based therapeutics
  • Detailed regulatory framework for drug approval in the U.S., Europe, and Japan